Jane Street
SABS icon

Jane Street’s SAB Biotherapeutics SABS Stock Holding History

Jane Street’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$883K Buy
226,500
+216,200
+2,099% +$804K ﹤0.01% 6791
2026
Q1 		$39.4K Buy
+10,300
New +$41.1K ﹤0.01% 11043

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jane Street's SABS Position: Q2 2026 in Review

Jane Street opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 14,634 shares worth $57.1K. The stake represents ﹤0.01% of the portfolio and ranks #10878 among its holdings. This is a return to the name: Jane Street previously reported a position in SABS as recently as Q3 2022.

Jane Street first reported a position in SABS in Q1 2021 and has held it in 5 quarters since. The position peaked at $360K in Q3 2021. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Jane Street held 14,634 shares of SAB Biotherapeutics worth $57.1K as of Q2 2026.
  • SAB Biotherapeutics was a new Jane Street position in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10878 holding.
  • Jane Street first reported a position in SAB Biotherapeutics in Q1 2021 and has held it in 5 quarters since.
  • Jane Street's SAB Biotherapeutics position peaked at $360K in Q3 2021.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.